Results: 59 patients were evaluated, including 53 with typical carcinoids and 6 with atypical carcinoid. 90% of the patients were submitted to surgery. The mean follow-up period was 57 months and the early post-operative mortality rate was 2% (one single case of palliative surgery). Histologic staging showed 49 patients in stage N0, one N1, eight N2 and one N3. The 5-year survival was 79.2%: 80.2% for typical carcinoids and 66.7% for atypical carcinoid (p < 0.05). The 5-year survival was 88.1% in T1 patients and 58.2% in T2-T4 patients (p < 0.01). In N0 patients, the 5-year survival was 89.7% while in N1-N3 it was 36% (p < 0.001). The 5-year survival was 85.9% in M0 disease and 0% in M1 disease (p < 0.01). Of the 11 patients who were submitted to adjuvant chemotherapy, 45.4% had atypical tumors. Discussion: In our sample, surgical treatment was safe, with a low postoperative complication rate. The prognosis was worse for atypical tumors, tumors with more than 3 cm, tumors with nodal involvement or metastasis. The five-year survival for typical carcinoid was excellent (80.2%), in agreement with the literature. For atypical carcinoid, the five-year was 66.7%, also similar to previous studies.
INTRODUCTION
Pulmonary carcinoid tumours are rare well-differentiated neuroendocrine tumours of the lung, corresponding to 0.4 to 3% of resected lung tumours and 23 to 30% of all neuroendocrine lung tumours. 1, 2 There are two types (typical and atypical) according to the 2004 World Health Organization (WHO) histological criteria. Typical carcinoid tumour is above 5 mm in size, presents with < 2 mitoses/2 mm 2 and necrosis is absent. In atypical carcinoid tumours there are 2-10 mitoses, necrosis or architectural distortion. 3 From a clinical perspective, these are usually central tumours progressing to bronchial obstruction. The most common symptoms include a cough or haemoptysis, although many patients present with no symptoms. 4, 5 They can affect people of all ages and there are no differences regarding gender. As regards outcome, when compared to other nonsmall cell lung carcinoma, carcinoid tumours usually present a favourable outcome upon surgical resection. Typical carcinoid tumours are rarely invasive and have a five-year survival rate between 87 and 100% 6-7 while atypical carcinoid have a higher risk of invasion and five-year survival rate between 25 and 69%. 8, 9 Few studies have assessed the outcome of carcinoid tumours according to the histological subtype, type or surgery, size of the tumour, lymphatic invasion and the presence of distant spread, following the new TNM classification. 10, 11 Our study aimed to characterise patients with carcinoid tumours and to analyse the factors that affected the outcome of patients attending to a tertiary healthcare unit.
MATERIAL AND METHODS
This was a retrospective study involving all patients diagnosed with lung carcinoid tumour attending a Hospital Unit in Centro Hospitalar e Universitário de Coimbra between 1999 and 2010. Data were obtained from patient's clinical record and included different epidemiological and clinical variables (including history and physical examination), technical procedures (including bronchoscopy, transthoracic biopsy and surgery) as well as outcome data. The histological diagnosis was confirmed by a neuroendocrine carcinomaexperienced pathologist and tumours were classified according to the WHO criteria. 3 Staging was carried out based on 2009 TNM classification for non-small cell lung cancer: T (Tumour); N (Nodes); M (Metastases). 12, 13 The statistical analysis used IBM's version 17 SPSS software. The five-year survival was estimated following the Kaplan and Meier method. Statistical significance was considered for p < 0.05.
RESULTS
Our study included 59 patients (33 male) and the mean age of the patients was 54.5 ± 14.5 (16 -79) (Fig. 1) .
According to the histological classification, 53 patients presented with a typical carcinoid tumour (TC) and six with an atypical carcinoid (AC). The description of our group of patients is shown in Table 1 .
Major patient's presentation symptom was a cough (47%), chest pain (34%), dyspnoea (29%), haemoptysis (15%) and Cushing's syndrome (2%), while 29% of the patients were asymptomatic. This neoplasm was diagnosed on chest CT-scan with a central nodule in 51% of the patients, a peripheral nodule in 34% and an image of atelectasis in 15%. From those patients presenting with central nodules (n = 30), most were located to the right upper and lower lobe. Tumour locations are shown in Table 2 .
When symptoms were compared to tumour location (central vs. peripheral), haemoptysis was more frequent in those patients with central tumours (p = 0.012). No statistical significant differences were found regarding dyspnoea, cough or chest pain.
Tumour staging is shown in Table 3 . The absence of lymphatic invasion was found in 49 patients (N0). In the group of patients with TC (n = 53 patients), 47 patients (89%) did not show any lymphatic involvement (N0), while in the AC group (6 patients), half of the patients presented in the N2 or N3 staging category.
As regards diagnosis, flexible bronchoscopy was performed in 69% (n = 41) of the patients and the tumour was identified in 90% of these (therefore considered as central). In central tumours (n = 37), 83% were TC. All these patients underwent a bronchial biopsy: a carcinoid tumour was identified in 76% of the patients, an inconclusive histological result was obtained in 21% and another lung neoplasm subtype was found in 3% of the patients. Trans-thoracic needle biopsy was performed in 12% of the patients and in 86% of these a carcinoid tumour was identified and showed another type of lung neoplasm in 14% of the patients. Most patients (n = 53; 90%) underwent surgery. The presence of an invasive cancer was the most frequent cause for non-surgical therapy (four patients); one patient underwent endoscopic therapy and one patient refused surgery. The surgical procedure involved a lobectomy in 64% of the patients, atypical sublobar resection in 26%, pneumectomy in 7% and bilobectomy in 4%. Radical mediastinal lymphadenectomy was also performed in all the patients. Operative mortality was 2% (one patient) and related to palliative surgery in a 57-year old patient with single contralateral lung invasion. Surgery involved the removal of a large right hilar mass with mediastinal and right atrial compression. Postoperative complications were observed in 24% of the patients: pleural effusion (n = 6; 10%), pneumothorax (n = 5; 8%), empyema (n = 1; 2%) and haemorrhage (n = 1; 2%), with a mean 57-month follow-up (0 -144). Fifteen patients died due to neoplasm-related (n = 9) and non-related causes (n = 6; three patients died due to myocardial heart infarction and three due to ischaemic stroke). From the deceased patients, 11 presented with TC and four with AC. Eight patients presented with an invasive cancer: two with AC and six with TC. From those with TC, four presented with lung invasion and two with liver invasion. The patients with AC presented with lung invasion. We did not find any differences regarding survival between the patients who underwent an atypical sub-lobar resection and those who underwent a lobar resection (Logrank; p = 0.359). A 79.2% five-year overall survival was found (Table 4) : 71.2 % in male patients and 90.4% in female patients (p > 0.05). In this study, a 90.9%, 77.1% and 76.2% five-year survival respectively related to the patient's age group (16- ). An 88.1% five-year survival was found in patients with T1 tumours (less than 3 cm in size) whereas in the remaining patients (T2-T4) it was 58.2% (p < 0.01). Stage N0 patients showed 89.7% fiveyear survival which was 36% in the remaining patients (N2-N3) (p < 0.001). Stage M0 patients showed 85.9% whereas stage M1 patients showed 0% five-year survival (p < 0.01). These results are shown in Table 3 . The analysis of survival using Kaplan-Meier curves is shown in Fig. 2 and 3 .
From the 11 patients with an indication to adjuvant chemotherapy, 45.4% were AC-patients. Chemotherapy involved the use of cisplatin and etoposide in all patients.
DISCUSSION
In our study, as expected 3, 12 , bronchopulmonary carcinoid tumours predominantly affected patients in their fifties, in a younger age group than patients with other lung neoplasms,, Similarly, a 1.26 male-to-female ratio was found, in line with what has been found by Filosso et al. 14-16 Most patients were symptomatic (71%), corresponding to a slightly higher percentage than what has been previously described. 16, 17 As regards primary location, most tumours were located in the upper lobes, unlike some clinical series that found the middle lobe as the predominant location for lung carcinoid tumours. 18 Bronchoscopy is a crucial test for a patient's evaluation as carcinoid tumours frequently present as central tumours. In our group of patients, 90% presented with central tumours, allowing for bronchial biopsies to be performed, contributing in turn to a timely diagnosis. However, the histological diagnosis based on the bronchial biopsy needs to be confirmed by the examination of the surgical sample. As previously described, the histological examination of the bronchial biopsy showed unspecific changes in 21% of the patients and another lung neoplasm subtype in 3%. Transthoracic needle biopsy showed to be important in peripheral tumours, not accessible by the bronchoscopy approach.
Most tumours considered as central (endoscopically visible tumours) were TC. Although the reason for this association is not be explained, this has already been described in other previous clinical series. 1 Surgical resection is the treatment of choice for lung carcinoid tumours. From the 53 patients who underwent surgery, 6 presented with lymphatic invasion (11%). Atypical sublobar resection in patients with central TC and no lymphatic invasion allows for optimal long-term survival.
2,17
Radical mediastinal lymphadenectomy should always be performed, although there are few studies regarding this issue. 19, 20 In our group of patients, surgery was found to be a safe approach, with a low rate of postoperative complications.
Atypical carcinoid tumours show higher risk of invasion and worse outcome than TC tumours. A worse outcome was found in patients with AC, in tumours with more than 3 cm in size, with lymphatic invasion and with distant spread. An excellent five-year survival was found in patients with TC (80.2%), in line with the literature. 1, 6 A 66.7% five-year survival was found in patients with AC, also in line with previous studies. 3, 6 No differences were found between atypical sub-lobar resection vs. lobar resection regarding patient's survival.
We should note that the fact that our study was carried out between 1999 and 2010 may represent a limitation, because other diagnostic and staging methods that have been introduced thereafter have changed clinical practice and will be the object of further studies.
CONCLUSION
Our group of patients showed similar characteristics to those previously described. Most patients presented with resectable carcinoid tumours and with a favourable outcome. Typical carcinoid tumours with no lymphatic invasion were the most frequently found subtypes. Histology (TC vs. AC), tumour's size, lymphatic invasion and the presence of distant spread were the factors related to worse outcome. 
